CVE-2026-25834

Exploitation

Assessed, none found. CISA's assessment recorded neither public exploit code nor evidence of exploitation when it was made.

SSVC decision

• ExploitationnoneCISA recorded no public exploit code and no evidence of exploitation.
• AutomatableyesAn attacker can reliably automate reconnaissance through exploitation, so this scales.
• Technical ImpactpartialSuccessful exploitation gives limited control of the vulnerable component.

CISA publishes the decision points, not a final SSVC decision. The decision also depends on mission and well-being impact, which is a property of your deployment rather than of the vulnerability.

EPSS probability

0.13% probability of exploitation activity in the next 30 days.

EPSS percentile

Equal to or higher than the score of 2.9% of scored records. A rank, not a probability.

NVD base score

6.5 (CVSS v3.x), scored by the NVD independently of the CNA.

NVD CVSS vector

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

NVD analysis status

Analyzed. NVD last modified this record on 2026-06-17.

Red Hat severity

Moderate. Red Hat's rating for its own products, not a CVSS rating.

Exploit-prediction scores from FIRST. Independent scoring and analysis status from the NVD. Vendor severity from Red Hat. Exploitation assessment and catalog membership from CISA.

Published

2026-04-01 00:00Z7 MO AGO

Last updated

2026-04-01 18:54Z7 MO AGO

Reserved

2026-02-06

Assigning CNA

mitre

Record state

PUBLISHED

Severity

Medium (CVSS 6.5)

CNA CVSS vector

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Weaknesses

• CWE-295Improper Certificate ValidationBase
• CWE-327Use of a Broken or Risky Cryptographic AlgorithmClass
• CWE-358Improperly Implemented Security Check for StandardBase

Data version

5.2

Document digest

ac77316a06053aa8e616b46497f1a0e9c58bfd251d1e1a470817b5ad1c9570f1

• mbed-tls.readthedocs.iohttps://mbed-tls.readthedocs.io/en/latest/security-advisories/
• mbed-tls.readthedocs.iohttps://mbed-tls.readthedocs.io/en/latest/security-advisories/mbedtls-security-advisory-2026-03-sigalg-injection/